LENZ Therapeutics Inc. (LENZ)
LENZ trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1815776/000181577626000011/0001815776-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LENZ on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001815776 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $19.1M |
| Net income | -$82.1M |
| Operating income | -$91.1M |
| Net margin | -430.3% |
| Operating margin | -477.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $25.2M |
| Total assets | $305.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $30.6M cash; operating cash flow -$31.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 31,420,583 (2026-10-28); 31,289,969 a year earlier; 57,996,481 three years earlier. 3y figure adjusted for split (1-for-7 overall). | Cover page 2026-10-28 |
| Reverse splits, 3 years | 1; latest 1-for-7 on 2024-03-22 | Source 2024-03-22 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $655K, sold $261K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $3.4M | -$31.0M | -$22.3M | $30.6M | No debt tags | $12.4M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $5.5M | -$31.9M | -$38.7M | $24.2M | No debt tags | $21.5M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $1.9M | -$41.5M | -$33.6M | $24.8M | No debt tags | $21.0M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $1.6M | -$35.9M | -$33.0M | $25.2M | No debt tags | $19.1M | 10-K 2026-03-24 |
| Q3 2025 2025-09-30 | $12.5M | -$16.7M | -$8.6M | $25.4M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $5.0M | -$14.9M | -$11.5M | $37.6M | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $0 | -$14.6M | -$16.0M | $23.0M | No debt tags | Needs four quarters | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | Not filed | -$12.7M | -$9.1M | $20.2M | No debt tags | $0 | 10-K 2026-03-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-04-14 |
| Latest annual report | 10-K | 2026-03-24 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-10-28 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 359 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +18.0% |
| 1 month | +21.5% |
| 3 months | -10.2% |
| Year to date | -74.2% |
| 1 year | -84.4% |
| From 52-week high | -87.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CMPX | Compass Therapeutics Inc. | $0.6615 | -14.51% | $119.1M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $0.9798 | -2.02% | $125.1M |
| ENGN | enGene Therapeutics Inc. | $1.89 | -21.58% | $126.7M |
| ARMP | Armata Pharmaceuticals Inc. | $2.99 | -22.74% | $111.2M |
| ZURA | Zura Bio Limited | $1.08 | -12.90% | $104.0M |
| FATE | Fate Therapeutics Inc. | $1.14 | -10.94% | $138.6M |
| VYGR | Voyager Therapeutics Inc. | $1.63 | -5.78% | $101.4M |
| MOLN | Molecular Partners AG | $2.70 | -8.21% | $101.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier